Association of FABP5 Expression with Poor Survival in Triple-negative Breast Cancer: Implication for Retinoic Acid Therapy

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2011 Mar 2

PMID 21356353

Citations 76

Authors

Rong-Zong Liu

Kathryn Graham

Darryl D Glubrecht

Devon R Germain

John R Mackey

Roseline Godbout

Affiliations

Soon will be listed here.

Abstract

Recent studies using animal models suggest that expression of FABP5 drives the stimulation of cell growth observed in estrogen receptor (ER)-negative breast cancer cells on exposure to retinoic acid (RA). The purpose of this study was to investigate the clinicopathological significance of FABP5 in breast cancer and to evaluate FABP5 as a prognostic marker and a possible novel therapeutic target in breast cancer. Gene expression microarray analysis revealed a significant correlation between elevated FABP5 RNA levels and ER/progesterone receptor (PR)-negative status, high tumor grade, and poor prognosis. Tissue microarray analysis demonstrated similar correlations with cytoplasmic FABP5 protein. Based on multivariate proportional regression analysis, cytoplasmic FABP5 is a significant and independent prognostic marker of overall survival and recurrence-free survival in breast cancer. The effects of FABP5 on tumor growth appear to be mediated primarily through cytoplasmic FABP, because no correlation was found between nuclear FABP5 and ER/PR-negative status, recurrence, and survival. FABP5 knockdown in breast cancer cell lines demonstrates a correlation between FABP5 levels and growth response to RA. We propose a model whereby growth-promoting FABP5 competes with growth-inhibiting CRABP2 for RA, with retention of RA in the cytoplasm by FABP5 preventing the inhibition of tumor growth.

Citing Articles

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment.

Wan M, Pan S, Shan B, Diao H, Jin H, Wang Z Mol Cancer. 2025; 24(1):61.

PMID: 40025508 PMC: 11874147. DOI: 10.1186/s12943-025-02258-1.

FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma.

Vecchio E, Gallo R, Mimmi S, Gentile D, Giordano C, Straface E Commun Biol. 2025; 8(1):324.

PMID: 40016284 PMC: 11868402. DOI: 10.1038/s42003-025-07754-0.

SBFI-26 enhances apoptosis in docetaxel-treated triple-negative breast cancer cells by increasing ROS levels.

He G, Liu M, Chen T, Huang L, Ke Y Bioimpacts. 2025; 15:30137.

PMID: 39963566 PMC: 11830146. DOI: 10.34172/bi.30137.

MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies.

Tang B, Xu W, Fang S, Zhu J, Qiu R, Shen L Mil Med Res. 2025; 12(1):5.

PMID: 39871325 PMC: 11773770. DOI: 10.1186/s40779-024-00588-7.

Diffusion-based generation of gene regulatory networks from scRNA-seq data with DigNet.

Wang C, Liu Z, Liu Z Genome Res. 2024; 35(2):340-354.

PMID: 39694856 PMC: 11874984. DOI: 10.1101/gr.279551.124.

References

Adamson J, Morgan E, Beesley C, Mei Y, Foster C, Fujii H . High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene. 2003; 22(18):2739-49. DOI: 10.1038/sj.onc.1206341. View

Munz M, Kieu C, Mack B, Schmitt B, Zeidler R, Gires O . The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene. 2004; 23(34):5748-58. DOI: 10.1038/sj.onc.1207610. View

Storch J, Corsico B . The emerging functions and mechanisms of mammalian fatty acid-binding proteins. Annu Rev Nutr. 2008; 28:73-95. DOI: 10.1146/annurev.nutr.27.061406.093710. View

Sussman F, de Lera A . Ligand recognition by RAR and RXR receptors: binding and selectivity. J Med Chem. 2005; 48(20):6212-9. DOI: 10.1021/jm050285w. View

Schug T, Berry D, Shaw N, Travis S, Noy N . Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell. 2007; 129(4):723-33. PMC: 1948722. DOI: 10.1016/j.cell.2007.02.050. View

Richardson A, Wang Z, De Nicolo A, Lu X, Brown M, Miron A . X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006; 9(2):121-32. DOI: 10.1016/j.ccr.2006.01.013. View

Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H . High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004; 86(3):207-13. DOI: 10.1023/B:BREA.0000036787.59816.01. View

Liao D, Dickson R . c-Myc in breast cancer. Endocr Relat Cancer. 2000; 7(3):143-64. DOI: 10.1677/erc.0.0070143. View

Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D . Identification of molecular apocrine breast tumours by microarray analysis. Oncogene. 2005; 24(29):4660-71. DOI: 10.1038/sj.onc.1208561. View

10.

Coller H, Grandori C, Tamayo P, Colbert T, Lander E, Eisenman R . Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A. 2000; 97(7):3260-5. PMC: 16226. DOI: 10.1073/pnas.97.7.3260. View

11.

Soprano K, Soprano D . Retinoic acid receptors and cancer. J Nutr. 2002; 132(12):3809S-3813S. DOI: 10.1093/jn/132.12.3809S. View

12.

Liu R, Li X, Godbout R . A novel fatty acid-binding protein (FABP) gene resulting from tandem gene duplication in mammals: transcription in rat retina and testis. Genomics. 2008; 92(6):436-45. DOI: 10.1016/j.ygeno.2008.08.003. View

13.

Conzen S . Minireview: nuclear receptors and breast cancer. Mol Endocrinol. 2008; 22(10):2215-28. PMC: 2582530. DOI: 10.1210/me.2007-0421. View

14.

Siegenthaler G, Hotz R, Didierjean L, Hellman U, Saurat J . Purification and characterization of the human epidermal fatty acid-binding protein: localization during epidermal cell differentiation in vivo and in vitro. Biochem J. 1994; 302 ( Pt 2):363-71. PMC: 1137237. DOI: 10.1042/bj3020363. View

15.

Tan N, Shaw N, Vinckenbosch N, Liu P, Yasmin R, Desvergne B . Selective cooperation between fatty acid binding proteins and peroxisome proliferator-activated receptors in regulating transcription. Mol Cell Biol. 2002; 22(14):5114-27. PMC: 139777. DOI: 10.1128/MCB.22.14.5114-5127.2002. View

16.

Edgar R, Domrachev M, Lash A . Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 2001; 30(1):207-10. PMC: 99122. DOI: 10.1093/nar/30.1.207. View

17.

Madsen P, Rasmussen H, Leffers H, Honore B, Celis J . Molecular cloning and expression of a novel keratinocyte protein (psoriasis-associated fatty acid-binding protein [PA-FABP]) that is highly up-regulated in psoriatic skin and that shares similarity to fatty acid-binding proteins. J Invest Dermatol. 1992; 99(3):299-305. DOI: 10.1111/1523-1747.ep12616641. View

18.

Shen Q, Brown P . Novel agents for the prevention of breast cancer: targeting transcription factors and signal transduction pathways. J Mammary Gland Biol Neoplasia. 2003; 8(1):45-73. DOI: 10.1023/a:1025783221557. View

19.

Huynh H, Larsson C, Narod S, Pollak M . Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res. 1995; 55(11):2225-31. View

20.

Zanardi S, Serrano D, Argusti A, Barile M, Puntoni M, DeCensi A . Clinical trials with retinoids for breast cancer chemoprevention. Endocr Relat Cancer. 2006; 13(1):51-68. DOI: 10.1677/erc.1.00938. View